Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Umoja Biopharma

- PMLiVE

AbbVie to expand immunology pipeline with $200m Nimble Therapeutics acquisition

The deal includes an IL23R inhibitor in preclinical development for psoriasis and inflammatory bowel disease

- PMLiVE

AbbVie’s Parkinson’s disease candidate tavapadon shows promise in phase 3 trial

More than ten million people worldwide are living with the neurodegenerative disorder

- PMLiVE

GSK and Rgenta to develop RNA-targeting small molecules in deal worth up to $500m per target

The alliance is aimed at advancing treatments for multiple disease areas, including oncology

- PMLiVE

Merck gains rights to LaNova’s PD-1/VEGF bispecific antibody in deal worth over $3.2bn

A phase 1 clinical trial of the candidate in advanced solid tumours is currently enrolling patients

- PMLiVE

Roche and Flare Therapeutics enter oncology partnership worth over $1.8bn

The companies will aim to discover small molecule treatments aimed at previously undrugged transcription factor targets

Daiichi Sankyo logo

Daiichi Sankyo enters $300m licensing deal with Alteogen to develop subcutaneous Enhertu

The company will use Alteogen’s hybrozyme technology to advance the formulation

- PMLiVE

AbbVie to expand neuroscience pipeline with $1.4bn Aliada Therapeutics acquisition

The deal includes a candidate in phase 1 development for Alzheimer's disease

- PMLiVE

Merck acquires oncology spinout Modifi Biosciences in deal worth $1.3bn

The agreement gives Merck access to a new class of small molecules for difficult-to-treat cancers

- PMLiVE

Pfizer and Triana enter molecular glue degrader partnership worth over $1.5bn

The companies will aim to discover new drugs for cancer and other severe diseases

- PMLiVE

AbbVie’s continuous Parkinson’s disease therapy Vyalev approved by FDA

More than ten million people worldwide are living with the neurological disorder

- PMLiVE

Sanofi and Orano Med partner to advance radioligand therapies for rare cancers

The companies will invest in a new entity that will operate under the Orano Med brand

- PMLiVE

AbbVie shares promising late-stage results for Parkinson’s disease candidate tavapadon

Approximately 153,000 people in the UK are currently living with the neurodegenerative disorder

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links